We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study.
- Authors
Oberhoff, C; Neri, B; Amadori, D; Petry, K U; Gamucci, T; Rebmann, U; Nowrousian, M R; Voigtmann, R; Monfardini, S; Armand, J P; Herrmann, R; Netter-Pinon, J; Tubiana-Mathieu, N; Zwierzina, H
- Abstract
Anemia is a common side effect of anticancer chemotherapy. Blood transfusion, previously the only available treatment for chemotherapy-induced anemia, may result in some clinical or subclinical adverse effects in the recipients. Recombinant human erythropoietin (rhEPO) provides a new treatment modality for chemotherapy-induced anemia.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Vol 9, Issue 3, p255
- ISSN
0923-7534
- Publication type
Journal Article
- DOI
10.1023/a:1008296622469